- Home
- NUVL vs PLXS Comparison
NUVL vs PLXS Comparison
Compare NUVL & PLXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- PLXS
- Stock Information
- Founded
- NUVL 2017
- PLXS 1979
- Country
- NUVL United States
- PLXS United States
- Employees
- NUVL N/A
- PLXS N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- PLXS Electrical Products
- Sector
- NUVL Health Care
- PLXS Technology
- Exchange
- NUVL Nasdaq
- PLXS Nasdaq
- Market Cap
- NUVL 4.9B
- PLXS 4.5B
- IPO Year
- NUVL 2021
- PLXS 1986
- Fundamental
- Price
- NUVL $87.24
- PLXS $153.54
- Analyst Decision
- NUVL Strong Buy
- PLXS Buy
- Analyst Count
- NUVL 10
- PLXS 5
- Target Price
- NUVL $112.60
- PLXS $133.50
- AVG Volume (30 Days)
- NUVL 492.9K
- PLXS 177.9K
- Earning Date
- NUVL 11-12-2024
- PLXS 10-23-2024
- Dividend Yield
- NUVL N/A
- PLXS N/A
- EPS Growth
- NUVL N/A
- PLXS N/A
- EPS
- NUVL N/A
- PLXS 4.01
- Revenue
- NUVL N/A
- PLXS $3,960,827,000.00
- Revenue This Year
- NUVL N/A
- PLXS $8.13
- Revenue Next Year
- NUVL N/A
- PLXS $10.48
- P/E Ratio
- NUVL N/A
- PLXS $38.33
- Revenue Growth
- NUVL N/A
- PLXS N/A
- 52 Week Low
- NUVL $56.52
- PLXS $90.18
- 52 Week High
- NUVL $113.51
- PLXS $169.41
- Technical
- Relative Strength Index (RSI)
- NUVL 38.02
- PLXS 56.73
- Support Level
- NUVL $89.62
- PLXS $152.05
- Resistance Level
- NUVL $96.24
- PLXS $167.32
- Average True Range (ATR)
- NUVL 2.90
- PLXS 4.09
- MACD
- NUVL -0.27
- PLXS -0.35
- Stochastic Oscillator
- NUVL 15.96
- PLXS 41.82
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About PLXS Plexus Corp.
Plexus Corp is a U.S based Electronic Manufacturing Services company that provides a range of services, from conceptualization and design to fulfilling orders and providing sustaining solutions, such as replenishment and refurbishment. The company's segments comprise AMER, APAC,ge and EMEA.